Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

FDA Found Bacteria in Recalled Tylenol

May 5, 2010 6:09 am | by Matthew Perrone | News | Comments

Ingredients used by Johnson & Johnson in some of the 40 varieties of children's cold medicines recalled last week were contaminated with bacteria, according to a report by the Food and Drug Administration.

TOPICS:

Novartis Settling Whistleblower Suit for $72.5M

May 5, 2010 6:05 am | News | Comments

Swiss pharmaceutical company Novartis AG is paying $72.5 million to settle a whistleblower lawsuit accusing it of improperly billing government programs for unapproved uses of a cystic fibrosis drug.

TOPICS:

Spectrophotometer

May 4, 2010 7:44 am | Product Releases | Comments

Thermo Fisher Scientific Inc. announced that its NanoDrop 2000c UV-Vis Spectrophotometer significantly improves the protein quantitation process.

TOPICS:
Advertisement

Coated Plates

May 4, 2010 7:36 am | Product Releases | Comments

G-Biosciences offers a large selection of coated 96-well plates, known as Well-Coated plates.

TOPICS:

Warnex And Epigenomics Sign Septin9 Agreement

May 4, 2010 7:31 am | News | Comments

Warnex Medical Laboratories, a division of Warnex Inc., and Epigenomics AG, have entered into a non-exclusive licensing agreement for Epigenomics' colorectal cancer biomarker Septin9.

TOPICS:

BMS Board Authorizes $3B Stock Buyback

May 4, 2010 7:23 am | News | Comments

Bristol-Myers Squibb Company announced its Board of Directors has authorized the repurchase of up to $3 billion of its common stock.

TOPICS:

Broccoli Component Limits Breast Cancer Stem Cells

May 4, 2010 7:08 am | News | Comments

A compound derived from broccoli could help prevent or treat breast cancer by targeting cancer stem cells--the small number of cells that fuel a tumor's growth--according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

TOPICS:

Signaling Pathways May Link Cancer and Neurodegeneration

May 4, 2010 6:59 am | News | Comments

At first glance, cancer and neurodegenerative diseases seem to have little in common, but the more that is learned about the signaling pathways that control cell division, differentiation, neuronal plasticity and cell death, the more apparent is the overlap between the two types of disease.

TOPICS:
Advertisement

CS-8635 Shows Greater Reduction in Blood Pressure

May 4, 2010 6:48 am | News | Comments

Currently under FDA review, CS-8635 combines three powerful blood pressure treatments with different mechanisms of action, Benicar (olmesartan medoxomil), amlodipine and hydrochlorothiazide.

TOPICS:

Cempra Announces TAKSTA Phase 2 Results

May 4, 2010 6:35 am | News | Comments

Cempra Pharmaceuticals announced positive results from its Phase 2 clinical trial evaluating the efficacy and tolerability of the novel front loading dosing regimen of TAKSTA, the company’s oral, anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotic.

TOPICS:

FDA Probes Prostate Cancer Drugs

May 4, 2010 6:24 am | News | Comments

The Food and Drug Administration is looking into data suggesting a group of prostate cancer drugs increase the risk of diabetes and heart disease.

TOPICS:

Lawsuit Filed Against Merck Over Gardasil

May 4, 2010 6:20 am | News | Comments

An Albuquerque woman has filed a lawsuit over a vaccine intended to protect women from cervical cancer, alleging it caused physical and behavioral problems in her teenage daughter.

TOPICS:

Gilead to Submit NDA for Combination Truvada-TMC278

May 4, 2010 6:10 am | News | Comments

Gilead Sciences, Inc. has obtained data supporting bioequivalence of a formulation of the fixed-dose combination of Truvada and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278.

TOPICS:

Spectroscopy Software

May 3, 2010 8:04 am | Product Releases | Comments

Thermo Fisher Scientific Inc. announced the latest release in its GRAMS Suite of spectroscopy software, an industry standard solution for visualizing, processing, reporting and managing spectroscopy data.

TOPICS:

xCELLigence Useful for Testing Cytotoxicity

May 3, 2010 7:54 am | Product Releases | Comments

Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading